Zymeworks BC (ZYME) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Zymeworks intends to commence the Share Repurchase Program with $140.0 million in share repurchases expected through 2028, with flexibility to adjust the pace of repurchases based on market opportunities, cash flow, and …

Zymeworks Inc. (ZYME) came out with quarterly earnings of $2.28 per share, missing the Zacks Consensus Estimate of $2.4 per share. This compares to a loss of $0.26 per share a year ago.…

VANCOUVER, British Columbia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, mult…

Zymeworks (NASDAQ: ZYME - Get Free Report) and Vericel (NASDAQ: VCEL - Get Free Report) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of th…

Zymeworks (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

Zymeworks NASDAQ: ZYME outlined a partnering-focused research strategy, presented updated clinical data for its ZW191 antibody-drug conjugate in platinum-resistant ovarian cancer, and discussed its recently announced col…

Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript…

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced the appointment …

VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multi…

VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multi…

VANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, mult…

Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026 Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026…

Zymeworks NASDAQ: ZYME said it has completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, an acquired research portfolio, collaboration and royalty economics, Irish tax attributes and a comm…

Zymeworks Inc. (ZYME) M&A Call Transcript…

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, mul…

Bank of America Corp DE purchased a new position in shares of Zymeworks Inc. (NASDAQ: ZYME) during a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund pur…

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, mult…

Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

Jupiter Topco LLC bought a new position in shares of Zymeworks Inc. (NASDAQ: ZYME) in a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought …

Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab's FDA approval. Zanidatamab's first-line HER2+ gastroesophageal cancer approval expa…

Bank of America Corp DE lifted its stake in Zymeworks Inc. (NASDAQ: ZYME) by 164.5% during a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm ow…

Deutsche Bank AG purchased a new stake in Zymeworks Inc. (NASDAQ: ZYME) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased …
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Jan 25. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

